PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-143.14%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
5.86%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
-142.73%
Negative net income growth while AXSM stands at 0.50%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-120.58%
Negative EPS growth while AXSM is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-120.58%
Negative diluted EPS growth while AXSM is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.21%
Share change of 10.21% while AXSM is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
10.21%
Diluted share change of 10.21% while AXSM is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
9.39%
Positive OCF growth while AXSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
9.37%
Positive FCF growth while AXSM is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56347.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-5186.83%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-34380.15%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-67208.18%
Negative 10Y net income/share CAGR while AXSM is at 38.49%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-8163.79%
Negative 5Y net income/share CAGR while AXSM is 38.49%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-121.82%
Negative 3Y CAGR while AXSM is 38.49%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
31995.75%
Equity/share CAGR of 31995.75% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
9371.92%
Equity/share CAGR of 9371.92% while AXSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
10880.98%
Equity/share CAGR of 10880.98% while AXSM is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Asset growth of 31.29% while AXSM is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
28.45%
BV/share growth of 28.45% while AXSM is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-51.38%
We’re deleveraging while AXSM stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-5.21%
Our R&D shrinks while AXSM invests at 14.98%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-6.73%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.